Indication
Non-Small-Cell Lung Carcinoma
11 clinical trials
24 products
4 drugs
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)Status:
Product
CapmatinibClinical trial
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).Status: Active (not recruiting), Estimated PCD: 2018-10-04
Product
MEDI4736Product
Paclitaxel + CarboplatinProduct
Gemcitabine + CisplatinProduct
Gemcitabine + CarboplatinProduct
Pemetrexed + CisplatinProduct
Pemetrexed + CarboplatinProduct
TremelimumabClinical trial
Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLCStatus: Active (not recruiting), Estimated PCD: 2025-11-27
Product
AZD2936Product
AlectinibClinical trial
Patient Profiles and Treatment Patterns Among ALK-positive NSCLC Patients Treated With AlectinibStatus: Completed, Estimated PCD: 2022-11-01
Clinical trial
An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, With Pembrolizumab, in Patients With Unresectable Stage III / IV Cutaneous Melanoma and With Stage IV NSCLC (PDL1≥ 50%)Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
GAd-PEVProduct
MVA-PEVClinical trial
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)Status: Completed, Estimated PCD: 2017-11-08
Product
CisplatinProduct
PemetrexedProduct
Saline solutionProduct
PembrolizumabProduct
CarboplatinProduct
DexamethasoneClinical trial
Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor TherapyStatus: Completed, Estimated PCD: 2022-01-20
Product
NivolumabProduct
IpilimumabClinical trial
Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20)Status: Terminated
Product
Epoetin AlfaClinical trial
A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy for Non-small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Radiation TherapyDrug
TiragolumabDrug
AN0025Product
Ascorbic AcidClinical trial
A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-04-21
Product
Pembrolizumab/VibostolimabDrug
mFOLFOX6Clinical trial
Phase II Trial of Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Drug
olaparib